Salspera Health filed for a $91 million IPO to advance saltikva, an engineered Salmonella strain expressing human IL‑2, into phase‑3 studies in metastatic pancreatic cancer and other solid tumors. The Cambridge biotech plans to use proceeds primarily to finance a pivotal phase‑3 study and scale its live biotherapeutics platform. Salspera’s SEC filing underscores investor appetite for novel microbial immunotherapies that combine tumor colonization with cytokine delivery; the company has orphan and fast‑track designations for selected indications and positions saltikva as an intratumoral activator of NK and CD8 T‑cell responses.